|Articles|February 1, 2012
- Pharmaceutical Executive-02-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - February 2012
Brand of the Year : Abbott's Humira
Advertisement
Articles in this issue
almost 14 years ago
How to Choose a Medical Animatoralmost 14 years ago
Money for Nothing, Patents for Free?almost 14 years ago
Trying Trials at GC-2almost 14 years ago
Prizing the Eye : Brent Saunders, CEO Bausch + Lombalmost 14 years ago
Brand Success: It's Not Serendipityalmost 14 years ago
Brazil Report: A Bold Player Bloomsalmost 14 years ago
Of Farms, Beaches … and Genericsalmost 14 years ago
FDA Social Media Guidelines: Irresponsible?almost 14 years ago
Time to Appoint a 'Chief Patient Officer'?almost 14 years ago
Japanese Knowledge Brought to BrazilNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
